However, we and other groups described that some RAS wt mCRC patients with clinical resistance to anti-EGFR agents had a liquid biopsy positive for KRAS mutations and carried the same variant at very low allelic frequency in the primary tumor [13,23]. The gene discussed is EGFR; the disease is neoplasm.